Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

Bill: 115-hr-5605
Sponsor: Rep. Ruiz, Raul [D-CA-36]
Introduced: 2018-04-24 in the House
Policy area: Health
Subjects: Congressional oversight
Drug therapy
Drug trafficking and controlled substances
Drug, alcohol, tobacco use
Government studies and investigations
Health care quality
Health personnel
Health programs administration and funding
Home and outpatient care
Hospital care
Medicare
Mental health
Performance measurement
Prescription drugs
User charges and fees

Summary:
action_date: 2018-04-24
text: 

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

 
This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access of opioid use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures. 

 
Opioid use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participating teams.
 
The CMS must adopt or develop program quality standards and performance methods.


action_date: 2018-06-12
text: 

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

 
This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures. 
 
Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants.
 


action_date: 2018-06-19
text: 

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

 
(Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures. 
 
Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants.
 
(Sec. 3) The bill also requires prescriptions for controlled substances that are covered under the Medicare prescription drug benefit or Medicare Advantage prescription drug plans to be transmitted via electronic prescription programs. The CMS may waive such requirements under specified circumstances.



Legislative actions:
action_date: 2018-06-20
text: Received in the Senate and Read twice and referred to the Committee on Finance.
action_date: 2018-06-19
text: The title of the measure was amended. Agreed to without objection.
action_date: 2018-06-19
text: Motion to reconsider laid on the table Agreed to without objection.
action_date: 2018-06-19
text: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)
action_date: 2018-06-19
text: Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)
action_date: 2018-06-19
text: DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.
action_date: 2018-06-19
text: Considered under suspension of the rules. (consideration: CR H5239-5243)
action_date: 2018-06-19
text: Mr. Walden moved to suspend the rules and pass the bill, as amended.
action_date: 2018-06-12
text: Placed on the Union Calendar, Calendar No. 578.
action_date: 2018-06-12
text: Committee on Ways and Means discharged.
action_date: 2018-06-12
text: Committee on Ways and Means discharged.
action_date: 2018-06-12
text: Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.
action_date: 2018-06-12
text: Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.
action_date: 2018-05-17
text: Ordered to be Reported (Amended) by Voice Vote.
action_date: 2018-05-17
text: Committee Consideration and Mark-up Session Held.
action_date: 2018-05-01
text: Referred to the Subcommittee on Health.
action_date: 2018-04-24
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2018-04-24
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2018-04-24
text: Introduced in House
action_date: 2018-04-24
text: Introduced in House